BDBM300049 (3,3- difluoroazetidin-1- yl)(2-{[(2R)-1- methoxypropan-2- yl]oxy}-6-[4-(4- methoxy-1H- pyrrolo[2,3- b]pyridin-3- yl)piperidin-1- yl]pyrimidin-4- yl)methanone::US9593097, Example 429
SMILES: COC[C@@H](C)Oc1nc(cc(n1)C(=O)N1CC(F)(F)C1)N1CCC(CC1)c1c[nH]c2nccc(OC)c12
InChI Key:
Data: 1 KI
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tyrosine-protein kinase receptor UFO (Homo sapiens (Human)) | BDBM300049 ((3,3- difluoroazetidin-1- yl)(2-{[(2R)-1- methoxyp...) | PDB KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 0.0180 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. US Patent | Assay Description AXL enzyme inhibition (% inhibition, Kiapp and Ki values) by small molecule inhibitors was evaluated using a fluorescence-based microfluidic mobility... | US Patent US9593097 (2017) BindingDB Entry DOI: 10.7270/Q2GM89BD | |||||||||||
More data for this Ligand-Target Pair |